[1] VINCENT VANHEULE. The Positively Charged COOH-terminal Glycosaminoglycan-binding CXCL9(74-103) Peptide Inhibits CXCL8-induced Neutrophil Extravasation and Monosodium Urate Crystal-induced Gout in Mice.[J]. The Journal of Biological Chemistry, 2015: 21292-21304. DOI:
10.1074/jbc.m115.649855[2] VINCENT VANHEULE . Basic chemokine-derived glycosaminoglycan binding peptides exert antiviral properties against dengue virus serotype 2, herpes simplex virus-1 and respiratory syncytial virus[J]. Biochemical pharmacology, 2016, 100: Pages 73-85. DOI:
10.1016/j.bcp.2015.11.001[3] PEDRO E. MARQUES. Inhibition of Drug-Induced Liver Injury in Mice Using a Positively Charged Peptide That Binds DNA[J]. Hepatology Communications, 2021, 5 10: 1737-1754. DOI:
10.1002/hep4.1759[4] D. BOFF. The Therapeutic Treatment with the GAG-Binding Chemokine Fragment CXCL9(74–103) Attenuates Neutrophilic Inflammation and Lung Dysfunction during Klebsiella pneumoniae Infection in Mice[J]. International Journal of Molecular Sciences, 2022. DOI:
10.3390/ijms23116246